Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sertraline + telenzepine is a combination of two pharmaceutical agents. Sertraline is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder. It works by selectively inhibiting the reuptake of serotonin at the presynaptic neuronal membrane in the central nervous system, thereby increasing serotonergic activity and improving mood and anxiety symptoms. Sertraline also exhibits some dopamine reuptake inhibition and sigma-1 receptor binding activity[1][2][3][5][7][8]. Telenzepine is an antimuscarinic agent that acts as a selective muscarinic M1 receptor antagonist; it has been investigated for use in peptic ulcer disease but is not widely marketed or approved in many countries.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sertraline + telenzepine.